 | • レポートコード：QY20ST-06915 • 出版社/出版日：QYResearch / 2020年9月15日 ※2025年版があります。お問い合わせください。 • レポート形態：英文、PDF、140ページ • 納品方法：Eメール（受注後2~3営業日） • 産業分類：医薬品、医療 |
| Single User | ￥580,000 (USD4,000) | ▷ お問い合わせ |
| Multi User | ￥870,000 (USD6,000) | ▷ お問い合わせ |
| Enterprise License | ￥1,160,000 (USD8,000) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査レポートでは、世界のゲムシタビン市場について種類別（1g/バイアル、200mg/バイアル）、用途別（病院薬局、小売薬局、オンライン薬局）、地域別（北米、ヨーロッパ、中国、日本、東南アジア、インド）に区分して調査し、纏めました。2015年～2026年までの市場規模予測、主要プレイヤーの競争状況・市場シェア・企業情報、製造コスト分析、販売チャネル・流通業者・顧客情報、市場動向・機会・課題などのマーケットデータが記載されています。市場予測データは新型コロナウイルスの影響を反映させました。 ・ゲムシタビン市場の概要 ・世界の主要地域別ゲムシタビン市場規模2015-2026 ・主要プレイヤーの競争状況・市場シェア ・世界のゲムシタビン市場規模2015-2026：種類別（1g/バイアル、200mg/バイアル） ・世界のゲムシタビン市場規模2015-2026：用途別（病院薬局、小売薬局、オンライン薬局） ・ゲムシタビンの北米市場規模2015-2020 ・ゲムシタビンのヨーロッパ市場規模2015-2020 ・ゲムシタビンの中国市場規模2015-2020 ・ゲムシタビンの日本市場規模2015-2020 ・ゲムシタビンの東南アジア市場規模2015-2020 ・ゲムシタビンのインド市場規模2015-2020 ・主要プレイヤーの企業情報：事業概要・売上・企業動向 ・ゲムシタビンの製造コスト分析 ・販売チャネル、流通業者、顧客 ・ゲムシタビンの市場動向・機会・課題 ・調査の結論 |
A recently published report by QY Research titled Global Gemcitabine (CAS 95058-81-4) Sales Market Report 2020 is designed in a way that helps the readers to acquire a complete knowledge about the overall market scenario and it’s most lucrative sectors. The research report also statistically provides accurate data in a statistical manner. It examines the historic accomplishments and recent opportunities present in the global Gemcitabine (CAS 95058-81-4) market. QY Research report focuses on the consumption, geography, by type, by application, and the competitive landscape. The 4000 version of the report mainly splits the data for each region to analyze the leading companies, applications, and product types.
QY Research aims to provide a complete knowledgeable report so that the readers will benefit from it. The report is properly examined and compiled by industry experts and will shed light on the key information that requires from the clients.
Report Overview:
Gemcitabine (CAS 95058-81-4), C9H11F2N3O4, the formula weight is 263.2, and its form is white to yellow powder.
Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost 100 countries around the globe with the World Health Organization declaring it a public health emergency. The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the Gemcitabine (CAS 95058-81-4) market in 2020.
COVID-19 can affect the global economy in three main ways: by directly affecting production and demand, by creating supply chain and market disruption, and by its financial impact on firms and financial markets.
The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor events restricted; over forty countries state of emergency declared; massive slowing of the supply chain; stock market volatility; falling business confidence, growing panic among the population, and uncertainty about future.
This report also analyses the impact of Coronavirus COVID-19 on the Gemcitabine (CAS 95058-81-4) industry.
Based on our recent survey, we have several different scenarios about the Gemcitabine (CAS 95058-81-4) YoY growth rate for 2020. The probable scenario is expected to grow by a xx% in 2020 and the revenue will be xx in 2020 from US$ xx million in 2019. The market size of Gemcitabine (CAS 95058-81-4) will reach xx in 2026, with a CAGR of xx% from 2020 to 2026.
QY Research report provides an overview and scope of the global Gemcitabine (CAS 95058-81-4) market, stating its drivers, trends, opportunities, and restraints. The report also comprises all key details of the global Gemcitabine (CAS 95058-81-4) market such as market strategies, sales volumes, and consumption. The report also covers the names of all distribution channels such as manufacturers, suppliers, wholesalers, distributors, consumers, and dealers.
QY Research also presents the statistical data in the form of infographics, tables, and charts to predict the trends and developments of the global Gemcitabine (CAS 95058-81-4) market over the forecast period. The research analysts have also used a framework such as key industry experts interview, research papers, refer journals, survey reports, and face-to-face interviews with expert professionals to know the detailed outlook of the global Gemcitabine (CAS 95058-81-4) market. The report also includes nautical information, where it shows Gemcitabine (CAS 95058-81-4) market product volume, utilization value, and production processes.
The research report also consists of a competitive landscape that describes the top players that are functioning in the global Gemcitabine (CAS 95058-81-4) market. This report also describes the key developments and trends, mergers and acquisitions strategies, and new product innovation that will show an enormous benefit to the companies that are competing in the global Gemcitabine (CAS 95058-81-4) market.
Gemcitabine is used as a second-line treatment for patients with advanced pancreatic cancer after fluorouracil failure, and can improve the quality of life of patients. Secondly, it is a first-line application for locally advanced (stage III) and already metastatic (stage IV) non-small cell lung cancer.
Geographical Analysis:
Based on region, the global Gemcitabine (CAS 95058-81-4) market is segmented into North America, Europe, China, Japan, Southeast Asia India and Other regions (Middle East & Africa, Central & South America). Research analysts have studied government initiatives, changing the political environment, and social scenarios that are likely to contribute to the growth of the regional markets.
Key Players:
The major players that are operating in the global Gemcitabine (CAS 95058-81-4) market are
Lilly France
Hansoh Pharma
Hisun Pharma
Pude Pharma
Qilu Pharma
Jari Pharma
HPGC
Yibantian Pharma
Actavis
Accord Healthcare
Mylan
Novartis
Salius Pharma
Segment by Type
1g/Vial
200mg/Vial
Segment by Application
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Competitive Landscape:
Factors such as cost analysis, marketing strategy, factor analysis, distributors, sourcing strategy, and industrial chain are all the parts of the global Gemcitabine (CAS 95058-81-4) market. The report also includes the analysis of the return on investment (ROI) feasibility with the estimated SWOT analysis.
The report covers the following objectives:
• Proliferation and maturation of trade in the global Gemcitabine (CAS 95058-81-4) market.
• The market share of the global Gemcitabine (CAS 95058-81-4) market, supply and demand ratio, growth revenue, supply chain analysis, and business overview.
• Current and future market trends that are influencing the growth opportunities and growth rate of the global Gemcitabine (CAS 95058-81-4) market.
• Feasibility study, new market insights, company profiles, investment return, revenue (value), and consumption (volume) of the global Gemcitabine (CAS 95058-81-4) market.
1 Gemcitabine (CAS 95058-81-4) Market Overview
1.1 Gemcitabine (CAS 95058-81-4) Product Scope
1.2 Gemcitabine (CAS 95058-81-4) Segment by Type
1.2.1 Global Gemcitabine (CAS 95058-81-4) Sales by Type (2020-2026)
1.2.2 1g/Vial
1.2.3 200mg/Vial
1.3 Gemcitabine (CAS 95058-81-4) Segment by Application
1.3.1 Global Gemcitabine (CAS 95058-81-4) Sales Comparison by Application (2020-2026)
1.3.2 Hospital Pharmacies
1.3.3 Retail Pharmacies
1.3.4 Online Pharmacies
1.4 Gemcitabine (CAS 95058-81-4) Market Estimates and Forecasts (2015-2026)
1.4.1 Global Gemcitabine (CAS 95058-81-4) Sales Growth Rate (2015-2026)
1.4.2 Global Gemcitabine (CAS 95058-81-4) Revenue and Growth Rate (2015-2026)
1.4.3 Global Gemcitabine (CAS 95058-81-4) Price Trends (2015-2026)
1.5 Coronavirus Disease 2019 (Covid-19): Gemcitabine (CAS 95058-81-4) Industry Impact
1.5.1 How the Covid-19 is Affecting the Gemcitabine (CAS 95058-81-4) Industry
1.5.1.1 Gemcitabine (CAS 95058-81-4) Business Impact Assessment – Covid-19
1.5.1.2 Supply Chain Challenges
1.5.1.3 COVID-19’s Impact On Crude Oil and Refined Products
1.5.2 Market Trends and Gemcitabine (CAS 95058-81-4) Potential Opportunities in the COVID-19 Landscape
1.5.3 Measures / Proposal against Covid-19
1.5.3.1 Government Measures to Combat Covid-19 Impact
1.5.3.2 Proposal for Gemcitabine (CAS 95058-81-4) Players to Combat Covid-19 Impact
2 Gemcitabine (CAS 95058-81-4) Estimate and Forecast by Region
2.1 Global Gemcitabine (CAS 95058-81-4) Market Size by Region: 2015 VS 2020 VS 2026
2.2 Global Gemcitabine (CAS 95058-81-4) Retrospective Market Scenario by Region (2015-2020)
2.2.1 Global Gemcitabine (CAS 95058-81-4) Sales Market Share by Region (2015-2020)
2.2.2 Global Gemcitabine (CAS 95058-81-4) Revenue Market Share by Region (2015-2020)
2.3 Global Gemcitabine (CAS 95058-81-4) Market Estimates and Forecasts by Region (2021-2026)
2.3.1 Global Gemcitabine (CAS 95058-81-4) Sales Estimates and Forecasts by Region (2021-2026)
2.3.2 Global Gemcitabine (CAS 95058-81-4) Revenue Forecast by Region (2021-2026)
2.4 Geographic Market Analysis: Market Facts & Figures
2.4.1 United States Gemcitabine (CAS 95058-81-4) Estimates and Projections (2015-2026)
2.4.2 Europe Gemcitabine (CAS 95058-81-4) Estimates and Projections (2015-2026)
2.4.3 China Gemcitabine (CAS 95058-81-4) Estimates and Projections (2015-2026)
2.4.4 Japan Gemcitabine (CAS 95058-81-4) Estimates and Projections (2015-2026)
2.4.5 Southeast Asia Gemcitabine (CAS 95058-81-4) Estimates and Projections (2015-2026)
2.4.6 India Gemcitabine (CAS 95058-81-4) Estimates and Projections (2015-2026)
3 Global Gemcitabine (CAS 95058-81-4) Competition Landscape by Players
3.1 Global Top Gemcitabine (CAS 95058-81-4) Players by Sales (2015-2020)
3.2 Global Top Gemcitabine (CAS 95058-81-4) Players by Revenue (2015-2020)
3.3 Global Gemcitabine (CAS 95058-81-4) Market Share by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Gemcitabine (CAS 95058-81-4) as of 2019)
3.4 Global Gemcitabine (CAS 95058-81-4) Average Price by Company (2015-2020)
3.5 Manufacturers Gemcitabine (CAS 95058-81-4) Manufacturing Sites, Area Served, Product Type
3.6 Manufacturers Mergers & Acquisitions, Expansion Plans
3.7 Primary Interviews with Key Gemcitabine (CAS 95058-81-4) Players (Opinion Leaders)
4 Global Gemcitabine (CAS 95058-81-4) Market Size by Type
4.1 Global Gemcitabine (CAS 95058-81-4) Historic Market Review by Type (2015-2020)
4.1.1 Global Gemcitabine (CAS 95058-81-4) Sales Market Share by Type (2015-2020)
4.1.2 Global Gemcitabine (CAS 95058-81-4) Revenue Market Share by Type (2015-2020)
4.1.3 Global Gemcitabine (CAS 95058-81-4) Price by Type (2014-2020)
4.2 Global Gemcitabine (CAS 95058-81-4) Market Estimates and Forecasts by Type (2021-2026)
4.2.1 Global Gemcitabine (CAS 95058-81-4) Sales Forecast by Type (2021-2026)
4.2.2 Global Gemcitabine (CAS 95058-81-4) Revenue Forecast by Type (2021-2026)
4.2.3 Global Gemcitabine (CAS 95058-81-4) Price Forecast by Type (2021-2026)
5 Global Gemcitabine (CAS 95058-81-4) Market Size by Application
5.1 Global Gemcitabine (CAS 95058-81-4) Historic Market Review by Application (2015-2020)
5.1.1 Global Gemcitabine (CAS 95058-81-4) Sales Market Share by Application (2015-2020)
5.1.2 Global Gemcitabine (CAS 95058-81-4) Revenue Market Share by Application (2015-2020)
5.1.3 Global Gemcitabine (CAS 95058-81-4) Price by Application (2015-2020)
5.2 Global Gemcitabine (CAS 95058-81-4) Market Estimates and Forecasts by Application (2021-2026)
5.2.1 Global Gemcitabine (CAS 95058-81-4) Sales Forecast by Application (2021-2026)
5.2.2 Global Gemcitabine (CAS 95058-81-4) Revenue Forecast by Application (2021-2026)
5.2.3 Global Gemcitabine (CAS 95058-81-4) Price Forecast by Application (2021-2026)
3 North America Gemcitabine (CAS 95058-81-4) Market Facts & Figures
3.2 North America Gemcitabine (CAS 95058-81-4) Sales Market Share by Company (2015-2020)
3.3 North America Gemcitabine (CAS 95058-81-4) Sales Market Share by Type (2015-2020)
3.4 North America Gemcitabine (CAS 95058-81-4) Sales Market Share by Application (2015-2020)
4 Europe Gemcitabine (CAS 95058-81-4) Market Facts & Figures
4.2 Europe Gemcitabine (CAS 95058-81-4) Sales Market Share by Company (2015-2020)
4.3 Europe Gemcitabine (CAS 95058-81-4) Sales Market Share by Type (2015-2020)
4.4 Europe Gemcitabine (CAS 95058-81-4) Sales Market Share by Application (2015-2020)
5 China Gemcitabine (CAS 95058-81-4) Market Facts & Figures
5.2 China Gemcitabine (CAS 95058-81-4) Sales Market Share by Company (2015-2020)
5.3 China Gemcitabine (CAS 95058-81-4) Sales Market Share by Type (2015-2020)
5.4 China Gemcitabine (CAS 95058-81-4) Sales Market Share by Application (2015-2020)
6 Japan Gemcitabine (CAS 95058-81-4) Market Facts & Figures
6.2 Japan Gemcitabine (CAS 95058-81-4) Sales Market Share by Company (2015-2020)
6.3 Japan Gemcitabine (CAS 95058-81-4) Sales Market Share by Type (2015-2020)
6.4 Japan Gemcitabine (CAS 95058-81-4) Sales Market Share by Application (2015-2020)
7 Southeast Asia Gemcitabine (CAS 95058-81-4) Market Facts & Figures
7.2 Southeast Asia Gemcitabine (CAS 95058-81-4) Sales Market Share by Company (2015-2020)
7.3 Southeast Asia Gemcitabine (CAS 95058-81-4) Sales Market Share by Type (2015-2020)
7.4 Southeast Asia Gemcitabine (CAS 95058-81-4) Sales Market Share by Application (2015-2020)
8 India Gemcitabine (CAS 95058-81-4) Market Facts & Figures
8.2 India Gemcitabine (CAS 95058-81-4) Sales Market Share by Company (2015-2020)
8.3 India Gemcitabine (CAS 95058-81-4) Sales Market Share by Type (2015-2020)
8.4 India Gemcitabine (CAS 95058-81-4) Sales Market Share by Application (2015-2020)
12 Company Profiles and Key Figures in Gemcitabine (CAS 95058-81-4) Business
12.1 Lilly France
12.1.1 Lilly France Gemcitabine (CAS 95058-81-4) Corporation Information
12.1.2 Lilly France Gemcitabine (CAS 95058-81-4) Business Overview and Total Revenue
12.1.3 Lilly France Gemcitabine (CAS 95058-81-4) Sales, Revenue and Gross Margin (2015-2020)
12.1.4 Lilly France Gemcitabine (CAS 95058-81-4) Products Offered
12.1.5 Lilly France Recent Development
12.2 Hansoh Pharma
12.2.1 Hansoh Pharma Gemcitabine (CAS 95058-81-4) Corporation Information
12.2.2 Hansoh Pharma Gemcitabine (CAS 95058-81-4) Business Overview and Total Revenue
12.2.3 Hansoh Pharma Gemcitabine (CAS 95058-81-4) Sales, Revenue and Gross Margin (2015-2020)
12.2.4 Hansoh Pharma Gemcitabine (CAS 95058-81-4) Products Offered
12.2.5 Hansoh Pharma Recent Development
12.3 Hisun Pharma
12.3.1 Hisun Pharma Gemcitabine (CAS 95058-81-4) Corporation Information
12.3.2 Hisun Pharma Gemcitabine (CAS 95058-81-4) Business Overview and Total Revenue
12.3.3 Hisun Pharma Gemcitabine (CAS 95058-81-4) Sales, Revenue and Gross Margin (2015-2020)
12.3.4 Hisun Pharma Gemcitabine (CAS 95058-81-4) Products Offered
12.3.5 Hisun Pharma Recent Development
12.4 Pude Pharma
12.4.1 Pude Pharma Gemcitabine (CAS 95058-81-4) Corporation Information
12.4.2 Pude Pharma Gemcitabine (CAS 95058-81-4) Business Overview and Total Revenue
12.4.3 Pude Pharma Gemcitabine (CAS 95058-81-4) Sales, Revenue and Gross Margin (2015-2020)
12.4.4 Pude Pharma Gemcitabine (CAS 95058-81-4) Products Offered
12.4.5 Pude Pharma Recent Development
12.5 Qilu Pharma
12.5.1 Qilu Pharma Gemcitabine (CAS 95058-81-4) Corporation Information
12.5.2 Qilu Pharma Gemcitabine (CAS 95058-81-4) Business Overview and Total Revenue
12.5.3 Qilu Pharma Gemcitabine (CAS 95058-81-4) Sales, Revenue and Gross Margin (2015-2020)
12.5.4 Qilu Pharma Gemcitabine (CAS 95058-81-4) Products Offered
12.5.5 Qilu Pharma Recent Development
12.6 Jari Pharma
12.6.1 Jari Pharma Gemcitabine (CAS 95058-81-4) Corporation Information
12.6.2 Jari Pharma Gemcitabine (CAS 95058-81-4) Business Overview and Total Revenue
12.6.3 Jari Pharma Gemcitabine (CAS 95058-81-4) Sales, Revenue and Gross Margin (2015-2020)
12.6.4 Jari Pharma Gemcitabine (CAS 95058-81-4) Products Offered
12.6.5 Jari Pharma Recent Development
12.7 HPGC
12.7.1 HPGC Gemcitabine (CAS 95058-81-4) Corporation Information
12.7.2 HPGC Gemcitabine (CAS 95058-81-4) Business Overview and Total Revenue
12.7.3 HPGC Gemcitabine (CAS 95058-81-4) Sales, Revenue and Gross Margin (2015-2020)
12.7.4 HPGC Gemcitabine (CAS 95058-81-4) Products Offered
12.7.5 HPGC Recent Development
12.8 Yibantian Pharma
12.8.1 Yibantian Pharma Gemcitabine (CAS 95058-81-4) Corporation Information
12.8.2 Yibantian Pharma Gemcitabine (CAS 95058-81-4) Business Overview and Total Revenue
12.8.3 Yibantian Pharma Gemcitabine (CAS 95058-81-4) Sales, Revenue and Gross Margin (2015-2020)
12.8.4 Yibantian Pharma Gemcitabine (CAS 95058-81-4) Products Offered
12.8.5 Yibantian Pharma Recent Development
12.9 Actavis
12.9.1 Actavis Gemcitabine (CAS 95058-81-4) Corporation Information
12.9.2 Actavis Gemcitabine (CAS 95058-81-4) Business Overview and Total Revenue
12.9.3 Actavis Gemcitabine (CAS 95058-81-4) Sales, Revenue and Gross Margin (2015-2020)
12.9.4 Actavis Gemcitabine (CAS 95058-81-4) Products Offered
12.9.5 Actavis Recent Development
12.10 Accord Healthcare
12.10.1 Accord Healthcare Gemcitabine (CAS 95058-81-4) Corporation Information
12.10.2 Accord Healthcare Gemcitabine (CAS 95058-81-4) Business Overview and Total Revenue
12.10.3 Accord Healthcare Gemcitabine (CAS 95058-81-4) Sales, Revenue and Gross Margin (2015-2020)
12.10.4 Accord Healthcare Gemcitabine (CAS 95058-81-4) Products Offered
12.10.5 Accord Healthcare Recent Development
12.11 Mylan
12.11.1 Mylan Gemcitabine (CAS 95058-81-4) Corporation Information
12.11.2 Mylan Gemcitabine (CAS 95058-81-4) Business Overview and Total Revenue
12.11.3 Mylan Gemcitabine (CAS 95058-81-4) Sales, Revenue and Gross Margin (2015-2020)
12.11.4 Mylan Gemcitabine (CAS 95058-81-4) Products Offered
12.11.5 Mylan Recent Development
12.12 Novartis
12.12.1 Novartis Gemcitabine (CAS 95058-81-4) Corporation Information
12.12.2 Novartis Gemcitabine (CAS 95058-81-4) Business Overview and Total Revenue
12.12.3 Novartis Gemcitabine (CAS 95058-81-4) Sales, Revenue and Gross Margin (2015-2020)
12.12.4 Novartis Gemcitabine (CAS 95058-81-4) Products Offered
12.12.5 Novartis Recent Development
12.13 Salius Pharma
12.13.1 Salius Pharma Gemcitabine (CAS 95058-81-4) Corporation Information
12.13.2 Salius Pharma Gemcitabine (CAS 95058-81-4) Business Overview and Total Revenue
12.13.3 Salius Pharma Gemcitabine (CAS 95058-81-4) Sales, Revenue and Gross Margin (2015-2020)
12.13.4 Salius Pharma Gemcitabine (CAS 95058-81-4) Products Offered
12.13.5 Salius Pharma Recent Development
13 Gemcitabine (CAS 95058-81-4) Manufacturing Cost Analysis
13.1 Gemcitabine (CAS 95058-81-4) Key Raw Materials Analysis
13.1.1 Key Raw Materials
13.1.2 Key Raw Materials Price Trend
13.1.3 Key Suppliers of Raw Materials
13.2 Proportion of Manufacturing Cost Structure
13.3 Manufacturing Process Analysis of Gemcitabine (CAS 95058-81-4)
13.4 Gemcitabine (CAS 95058-81-4) Industrial Chain Analysis
14 Marketing Channel, Distributors and Customers
14.1 Marketing Channel
14.2 Gemcitabine (CAS 95058-81-4) Distributors List
14.3 Gemcitabine (CAS 95058-81-4) Customers
15 Market Dynamics
15.1 Market Trends
15.2 Opportunities and Drivers
15.3 Challenges
15.4 Porter’s Five Forces Analysis
16 Research Findings and Conclusion
17 Appendix
17.1 Research Methodology
17.1.1 Methodology/Research Approach
17.1.2 Data Source
17.2 Author List
17.3 Disclaimer
Table 1. Global Gemcitabine (CAS 95058-81-4) Sales (Kg) Growth Rate by Type (2020-2026)
Table 2. Global Gemcitabine (CAS 95058-81-4) Sales (Kg) Comparison by Application (2020-2026)
Table 3. COVID-19 Impact Global Market: (Four Gemcitabine (CAS 95058-81-4) Market Size Forecast Scenarios)
Table 4. Opportunities and Trends for Gemcitabine (CAS 95058-81-4) Players in the COVID-19 Landscape
Table 5. Present Opportunities in China & Elsewhere Due to the Coronavirus Crisis
Table 6. Key Regions/Countries Measures against Covid-19 Impact
Table 7. Proposal for Gemcitabine (CAS 95058-81-4) Players to Combat Covid-19 Impact
Table 8. Global Market Gemcitabine (CAS 95058-81-4) Market Size (US$ Million) by Region:2015 VS 2020 &2026
Table 9. Global Gemcitabine (CAS 95058-81-4) Sales (Kg) by Region (2015-2020)
Table 10. Global Gemcitabine (CAS 95058-81-4) Sales Market Share by Region (2015-2020)
Table 11. Global Gemcitabine (CAS 95058-81-4) Revenue (US$ Million) Market Share by Region (2015-2020))
Table 12. Global Gemcitabine (CAS 95058-81-4) Revenue Share by Region (2015-2020)
Table 13. Global Gemcitabine (CAS 95058-81-4) Sales (Kg) Forecast by Region (2021-2026)
Table 14. Global Gemcitabine (CAS 95058-81-4) Sales Market Share Forecast by Region (2021-2026)
Table 15. Global Gemcitabine (CAS 95058-81-4) Revenue (US$ Million) Forecast by Region (2021-2026)
Table 16. Global Gemcitabine (CAS 95058-81-4) Revenue Share Forecast by Region (2021-2026)
Table 17. Global Gemcitabine (CAS 95058-81-4) (Kg) of Key Companies (2015-2020)
Table 18. Global Gemcitabine (CAS 95058-81-4) Sales Share by Company (2015-2020)
Table 19. Global Gemcitabine (CAS 95058-81-4) Revenue (US$ Million) by Company (2015-2020)
Table 20. Global Gemcitabine (CAS 95058-81-4) Revenue Share by Company (2015-2020)
Table 21. Global Gemcitabine (CAS 95058-81-4) by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Gemcitabine (CAS 95058-81-4) as of 2019)
Table 22. Global Gemcitabine (CAS 95058-81-4) Average Price (USD/Kg) of Key Company (2015-2020)
Table 23. Manufacturers Gemcitabine (CAS 95058-81-4) Manufacturing Sites and Area Served
Table 24. Manufacturers Gemcitabine (CAS 95058-81-4) Product Type
Table 25. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 26. Main Points Interviewed from Key Gemcitabine (CAS 95058-81-4) Players
Table 27. Global Gemcitabine (CAS 95058-81-4) Sales (Kg) by Type (2015-2020)
Table 28. Global Gemcitabine (CAS 95058-81-4) Sales Share by Type (2015-2020)
Table 29. Global Gemcitabine (CAS 95058-81-4) Revenue (US$ Million) Market Share by Type (2015-2020)
Table 30. Global Gemcitabine (CAS 95058-81-4) Price (Kg) by Type (2015-2020)
Table 31. Global Gemcitabine (CAS 95058-81-4) Sales Share by Type (2021-2026)
Table 32. Global Gemcitabine (CAS 95058-81-4) Revenue (US$ Million) Market Share by Type (2021-2026)
Table 33. Global Gemcitabine (CAS 95058-81-4) Revenue Share by Type (2021-2026)
Table 34. Global Gemcitabine (CAS 95058-81-4) Price (Kg) by Type (2021-2026)
Table 35. Global Gemcitabine (CAS 95058-81-4) Sales (Kg) by Application (2015-2020)
Table 36. Global Gemcitabine (CAS 95058-81-4) Sales Share by Application (2015-2020)
Table 37. Global Gemcitabine (CAS 95058-81-4) Revenue (US$ Million) Market Share by Application (2015-2020)
Table 38. Global Gemcitabine (CAS 95058-81-4) Price (Kg) by Application (2015-2020)
Table 39. Global Gemcitabine (CAS 95058-81-4) Sales (Kg) by Application (2021-2026)
Table 40. Global Gemcitabine (CAS 95058-81-4) Sales Share by Application (2021-2026)
Table 41. Global Gemcitabine (CAS 95058-81-4) Revenue (US$ Million) Market Share by Application (2021-2026)
Table 42. Global Gemcitabine (CAS 95058-81-4) Revenue Share by Application (2021-2026)
Table 43. Global Gemcitabine (CAS 95058-81-4) Price (Kg) by Application (2021-2026)
Table 44. United States Gemcitabine (CAS 95058-81-4) Sales (Kg) by Company (2015-2020)
Table 45. United States Gemcitabine (CAS 95058-81-4) Sales Market Share by Company (2015-2020)
Table 46. United States Gemcitabine (CAS 95058-81-4) Sales (Kg) by Type (2015-2020)
Table 47. United States Gemcitabine (CAS 95058-81-4) Sales Market Share by Type (2015-2020)
Table 48. United States Gemcitabine (CAS 95058-81-4) Sales (Kg) by Application (2015-2020)
Table 49. United States Gemcitabine (CAS 95058-81-4) Sales Market Share by Application (2015-2020)
Table 50. Europe Gemcitabine (CAS 95058-81-4) Sales (Kg) by Company (2015-2020)
Table 51. Europe Gemcitabine (CAS 95058-81-4) Sales Market Share by Company (2015-2020)
Table 52. Europe Gemcitabine (CAS 95058-81-4) Sales (Kg) by Type (2015-2020)
Table 53. Europe Gemcitabine (CAS 95058-81-4) Sales Market Share by Type (2015-2020)
Table 54. Europe Gemcitabine (CAS 95058-81-4) Sales (Kg) by Application (2015-2020)
Table 55. Europe Gemcitabine (CAS 95058-81-4) Sales Market Share by Type (2015-2020)
Table 56. China Gemcitabine (CAS 95058-81-4) Sales (Kg) by Company (2015-2020)
Table 57. China Gemcitabine (CAS 95058-81-4) Sales Market Share by Company (2015-2020)
Table 58. China Gemcitabine (CAS 95058-81-4) Sales (Kg) by Type (2015-2020)
Table 59. China Gemcitabine (CAS 95058-81-4) Sales Market Share by Type (2015-2020)
Table 60. China Gemcitabine (CAS 95058-81-4) Sales (Kg) by Application (2015-2020)
Table 61. China Gemcitabine (CAS 95058-81-4) Sales Market Share by Application (2015-2020)
Table 62. Japan Gemcitabine (CAS 95058-81-4) Sales (Kg) by Company (2015-2020)
Table 63. Japan Gemcitabine (CAS 95058-81-4) Sales Market Share by Company (2015-2020)
Table 64. Japan Gemcitabine (CAS 95058-81-4) Sales (Kg) by Type (2015-2020)
Table 65. Japan Gemcitabine (CAS 95058-81-4) Sales Market Share by Type (2015-2020)
Table 66. Japan Gemcitabine (CAS 95058-81-4) Sales (Kg) by Application (2015-2020)
Table 67. Japan Gemcitabine (CAS 95058-81-4) Sales Market Share by Application (2015-2020)
Table 68. Southeast Asia Gemcitabine (CAS 95058-81-4) Sales (Kg) by Company (2015-2020)
Table 69. Southeast Asia Gemcitabine (CAS 95058-81-4) Sales Market Share by Company (2015-2020)
Table 70. Southeast Asia Gemcitabine (CAS 95058-81-4) Sales (Kg) by Type (2015-2020)
Table 71. Southeast Asia Gemcitabine (CAS 95058-81-4) Sales Market Share by Type (2015-2020)
Table 72. Southeast Asia Gemcitabine (CAS 95058-81-4) Sales (Kg) by Type (2015-2020)
Table 73. Southeast Asia Gemcitabine (CAS 95058-81-4) Sales Market Share by Application (2015-2020)
Table 74. India Gemcitabine (CAS 95058-81-4) Sales (Kg) by Company (2015-2020)
Table 75. India Gemcitabine (CAS 95058-81-4) Sales Market Share by Company (2015-2020)
Table 76. India Gemcitabine (CAS 95058-81-4) Sales (Kg) by Type (2015-2020)
Table 77. India Gemcitabine (CAS 95058-81-4) Sales Market Share by Type (2015-2020)
Table 78. India Gemcitabine (CAS 95058-81-4) Sales (Kg) by Application (2015-2020)
Table 79. India Gemcitabine (CAS 95058-81-4) Sales Market Share by Application (2015-2020)
Table 80. Lilly France Corporation Information
Table 81. Lilly France Description and Business Overview
Table 82. Lilly France Gemcitabine (CAS 95058-81-4) Sales (Kg), Revenue (Million USD), Price (USD/Kg) and Gross Margin (2015-2020)
Table 83. Lilly France Gemcitabine (CAS 95058-81-4) Product
Table 84. Lilly France Recent Development
Table 85. Hansoh Pharma Corporation Information
Table 86. Hansoh Pharma Description and Business Overview
Table 87. Hansoh Pharma Gemcitabine (CAS 95058-81-4) Sales (Kg), Revenue (Million USD), Price (USD/Kg) and Gross Margin (2015-2020)
Table 88. Hansoh Pharma Gemcitabine (CAS 95058-81-4) Product
Table 89. Hansoh Pharma Recent Development
Table 90. Hisun Pharma Corporation Information
Table 91. Hisun Pharma Description and Business Overview
Table 92. Hisun Pharma Gemcitabine (CAS 95058-81-4) Sales (Kg), Revenue (Million USD), Price (USD/Kg) and Gross Margin (2015-2020)
Table 93. Hisun Pharma Gemcitabine (CAS 95058-81-4) Product
Table 94. Hisun Pharma Recent Development
Table 95. Pude Pharma Corporation Information
Table 96. Pude Pharma Description and Business Overview
Table 97. Pude Pharma Gemcitabine (CAS 95058-81-4) Sales (Kg), Revenue (Million USD), Price (USD/Kg) and Gross Margin (2015-2020)
Table 98. Pude Pharma Gemcitabine (CAS 95058-81-4) Product
Table 99. Pude Pharma Recent Development
Table 100. Qilu Pharma Corporation Information
Table 101. Qilu Pharma Description and Business Overview
Table 102. Qilu Pharma Gemcitabine (CAS 95058-81-4) Sales (Kg), Revenue (Million USD), Price (USD/Kg) and Gross Margin (2015-2020)
Table 103. Qilu Pharma Gemcitabine (CAS 95058-81-4) Product
Table 104. Qilu Pharma Recent Development
Table 105. Jari Pharma Corporation Information
Table 106. Jari Pharma Description and Business Overview
Table 107. Jari Pharma Gemcitabine (CAS 95058-81-4) Sales (Kg), Revenue (Million USD), Price (USD/Kg) and Gross Margin (2015-2020)
Table 108. Jari Pharma Gemcitabine (CAS 95058-81-4) Product
Table 109. Jari Pharma Recent Development
Table 110. HPGC Corporation Information
Table 111. HPGC Description and Business Overview
Table 112. HPGC Gemcitabine (CAS 95058-81-4) Sales (Kg), Revenue (Million USD), Price (USD/Kg) and Gross Margin (2015-2020)
Table 113. HPGC Gemcitabine (CAS 95058-81-4) Product
Table 114. HPGC Recent Development
Table 115. Yibantian Pharma Corporation Information
Table 116. Yibantian Pharma Gemcitabine (CAS 95058-81-4) Sales (Kg), Revenue (Million USD), Price (USD/Kg) and Gross Margin (2015-2020)
Table 117. Yibantian Pharma Description and Business Overview
Table 118. Yibantian Pharma Gemcitabine (CAS 95058-81-4) Product
Table 119. Yibantian Pharma Recent Development
Table 120. Actavis Corporation Information
Table 121. Actavis Gemcitabine (CAS 95058-81-4) Sales (Kg), Revenue (Million USD), Price (USD/Kg) and Gross Margin (2015-2020)
Table 122. Actavis Description and Business Overview
Table 123. Actavis Gemcitabine (CAS 95058-81-4) Product
Table 124. Actavis Recent Development
Table 125. Accord Healthcare Corporation Information
Table 126. Accord Healthcare Description and Business Overview
Table 127. Accord Healthcare Gemcitabine (CAS 95058-81-4) Sales (Kg), Revenue (Million USD), Price (USD/Kg) and Gross Margin (2015-2020)
Table 128. Accord Healthcare Gemcitabine (CAS 95058-81-4) Product
Table 129. Accord Healthcare Recent Development
Table 130. Mylan Corporation Information
Table 131. Mylan Description and Business Overview
Table 132. Mylan Gemcitabine (CAS 95058-81-4) Sales (Kg), Revenue (Million USD), Price (USD/Kg) and Gross Margin (2015-2020)
Table 133. Mylan Gemcitabine (CAS 95058-81-4) Product
Table 134. Mylan Recent Development
Table 135. Novartis Corporation Information
Table 136. Novartis Description and Business Overview
Table 137. Novartis Gemcitabine (CAS 95058-81-4) Sales (Kg), Revenue (Million USD), Price (USD/Kg) and Gross Margin (2015-2020)
Table 138. Novartis Gemcitabine (CAS 95058-81-4) Product
Table 139. Novartis Recent Development
Table . Salius Pharma Corporation Information
Table . Salius Pharma Description and Business Overview
Table . Salius Pharma Gemcitabine (CAS 95058-81-4) Sales (Kg), Revenue (Million USD), Price (USD/Kg) and Gross Margin (2015-2020)
Table . Salius Pharma Gemcitabine (CAS 95058-81-4) Product
Table . Salius Pharma Recent Development
Table 145. Production Base and Market Concentration Rate of Raw Material
Table 146. Key Suppliers of Raw Materials
Table 147. Gemcitabine (CAS 95058-81-4) Distributors List
Table 148. Gemcitabine (CAS 95058-81-4) Customers List
Table 149. Market Key Trends
Table 150. Key Opportunities and Drivers: Impact Analysis (2020-2026)
Table 151. Key Challenges
Table 152. Research Programs/Design for This Report
Table 153. Key Data Information from Secondary Sources
Table 154. Key Data Information from Primary Sources
List of Figures
Figure 1. Gemcitabine (CAS 95058-81-4) Product Picture
Figure 2. Global Gemcitabine (CAS 95058-81-4) Sales Market Share by Type in 2020 & 2026
Figure 3. Type I Product Picture
Figure 4. Type II Product Picture
Figure 5. Global Gemcitabine (CAS 95058-81-4) Market Share by Application in 2020 & 2026
Figure 6. Hospital Pharmacies Examples
Figure 7. Retail Pharmacies Examples
Figure 8. Online Pharmacies Examples
Figure 9. Global Gemcitabine (CAS 95058-81-4) Sales (Kg) Growth Rate (2015-2026)
Figure 10. Global Gemcitabine (CAS 95058-81-4) Revenue (US$ Million) Growth Rate (2015-2026)
Figure 11. Global Gemcitabine (CAS 95058-81-4) Price Trends Growth Rate (2015-2026) (USD/Kg)
Figure 12. Global Gemcitabine (CAS 95058-81-4) Revenue Market Share by Region: 2015 VS 2020
Figure 13. Global Gemcitabine (CAS 95058-81-4) Revenue Market Share by Region: 2021 VS 2026
Figure 14. United States Gemcitabine (CAS 95058-81-4) Revenue (Million USD) Growth Rate (2015-2026)
Figure 15. United States Gemcitabine (CAS 95058-81-4) Sales (Kg) Growth Rate (2015-2026)
Figure 16. Europe Gemcitabine (CAS 95058-81-4) Revenue (Million USD) Growth Rate (2015-2026)
Figure 17. Europe Gemcitabine (CAS 95058-81-4) Sales (Million USD) Growth Rate (2015-2026)
Figure 18. China Gemcitabine (CAS 95058-81-4) Revenue (Million USD) Growth Rate (2015-2026)
Figure 19. China Gemcitabine (CAS 95058-81-4) Sales (Million USD) and Growth Rate (2015-2026)
Figure 20. Japan Gemcitabine (CAS 95058-81-4) Revenue (Million USD) Growth Rate (2015-2026)
Figure 21. Japan Gemcitabine (CAS 95058-81-4) Sales (Million USD) Growth Rate (2015-2026)
Figure 22. Southeast Asia Gemcitabine (CAS 95058-81-4) Revenue (Million USD) Growth Rate (2015-2026)
Figure 23. Southeast Asia Gemcitabine (CAS 95058-81-4) Sales (Million USD) Growth Rate (2015-2026)
Figure 24. India Gemcitabine (CAS 95058-81-4) Revenue (Million USD) Growth Rate (2015-2026)
Figure 25. India Gemcitabine (CAS 95058-81-4) Sales (Million USD) Growth Rate (2015-2026)
Figure 26. Global 5 Largest Gemcitabine (CAS 95058-81-4) Players Market Share by Revenue in Gemcitabine (CAS 95058-81-4) 2015 & 2019
Figure 27. Gemcitabine (CAS 95058-81-4) Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
Figure 28. Global Gemcitabine (CAS 95058-81-4) Revenue Share by Type (2015-2020)
Figure 29. Global Gemcitabine (CAS 95058-81-4) Revenue Growth Rate by Type in 2015 & 2019
Figure 30. Global Gemcitabine (CAS 95058-81-4) Revenue Share by Application (2015-2020)
Figure 31. Global Gemcitabine (CAS 95058-81-4) Revenue Growth Rate by Application in 2015 & 2019
Figure 32. United States Gemcitabine (CAS 95058-81-4) Sales Market Share by Type in 2019
Figure 33. United States Gemcitabine (CAS 95058-81-4) Sales Market Share by Type in 2019
Figure 34. Europe Gemcitabine (CAS 95058-81-4) Sales Market Share by Company in 2019
Figure 35. Europe Gemcitabine (CAS 95058-81-4) Sales Market Share by Type in 2019
Figure 36. Europe Gemcitabine (CAS 95058-81-4) Sales Market Share by Application in 2019
Figure 37. China Gemcitabine (CAS 95058-81-4) Sales Market Share by Company in 2019
Figure 38. China Gemcitabine (CAS 95058-81-4) Sales Market Share by Type in 2019
Figure 39. China Gemcitabine (CAS 95058-81-4) Sales Market Share by Application in 2019
Figure 40. Japan Gemcitabine (CAS 95058-81-4) Sales Market Share by Company in 2019
Figure 41. Japan Gemcitabine (CAS 95058-81-4) Sales Market Share by Type in 2019
Figure 42. Japan Gemcitabine (CAS 95058-81-4) Sales Market Share by Application in 2019
Figure 43. Southeast Asia Gemcitabine (CAS 95058-81-4) Sales Market Share by Company in 2019
Figure 44. Southeast Asia Gemcitabine (CAS 95058-81-4) Sales Market Share by Type in 2019
Figure 45. Southeast Asia Gemcitabine (CAS 95058-81-4) Sales Market Share by Application in 2019
Figure 46. India Gemcitabine (CAS 95058-81-4) Sales Market Share by Company in 2019
Figure 47. India Gemcitabine (CAS 95058-81-4) Sales Market Share by Type in 2019
Figure 48. India Gemcitabine (CAS 95058-81-4) Sales Market Share by Application in 2019
Figure 49. Lilly France Total Revenue (US$ Million): 2019 Compared with 2018
Figure 50. Hansoh Pharma Total Revenue (US$ Million): 2019 Compared with 2018
Figure 51. Hisun Pharma Total Revenue (US$ Million): 2019 Compared with 2018
Figure 52. Pude Pharma Total Revenue (US$ Million): 2019 Compared with 2018
Figure 53. Qilu Pharma Total Revenue (US$ Million): 2019 Compared with 2018
Figure 54. Jari Pharma Total Revenue (US$ Million): 2019 Compared with 2018
Figure 55. HPGC Total Revenue (US$ Million): 2019 Compared with 2018
Figure 56. Yibantian Pharma Total Revenue (US$ Million): 2019 Compared with 2018
Figure 57. Actavis Total Revenue (US$ Million): 2019 Compared with 2018
Figure 58. Accord Healthcare Total Revenue (US$ Million): 2019 Compared with 2018
Figure 59. Mylan Total Revenue (US$ Million): 2019 Compared with 2018
Figure 60. Novartis Total Revenue (US$ Million): 2019 Compared with 2018
Figure 61. Salius Pharma Total Revenue (US$ Million): 2019 Compared with 2018
Figure 62. Key Raw Materials Price Trend
Figure 63. Manufacturing Cost Structure of Gemcitabine (CAS 95058-81-4)
Figure 64. Manufacturing Process Analysis of Gemcitabine (CAS 95058-81-4)
Figure 65. Gemcitabine (CAS 95058-81-4) Industrial Chain Analysis
Figure 66. Channels of Distribution
Figure 67. Distributors Profiles
Figure 68. Porter's Five Forces Analysis
Figure 69. Bottom-up and Top-down Approaches for This Report
Figure 70. Data Triangulation
Figure 71. Key Executives Interviewed
胆管がんの世界市場 2020年：企業別・地域別・種類別・用途別市場予測 Market Overview The global Bile Duct Cancer market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of 6.7% in the forecast period of 2020 to 2025 and will expected to reach USD 202.1 million by 2025, from USD 156.2 million in 2019. The Bile Duct Cancer mark…- 胆管がん治療薬の世界市場 2020年：企業別、地域別、種類・用途別 Market Overview The global Bile Duct Cancer Drugs market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Bile Duct Cancer Drugs…
- 胆管がん治療薬の世界市場 2020年：企業別、地域別、種類・用途別 Market Overview The global Bile Duct Cancer Drugs market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Bile Duct Cancer Drugs…
- 極低温バイアルラックの世界市場レポート2020 A recently published report by QY Research titled Global Cryogenic Vial Rack Sales Market Report 2020 is designed in a way that helps the readers to acquire a complete knowledge about the overall market scenario and it’s most lucrative sectors. The research report also statistically provides accurat…
- 特殊バイアルの世界市場レポート2020 A recently published report by QY Research titled Global Speciality Vial Sales Market Report 2020 is designed in a way that helps the readers to acquire a complete knowledge about the overall market scenario and it’s most lucrative sectors. The research report also statistically provides accurate da…